What does this research mean for the field?

The latency-associated antigen Rv2656c exhibits strong immunogenicity and provides immune protection against Mycobacterium tuberculosis, significantly reducing bacterial load in latent infections. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To identify and validate latency-associated antigens with immune-protective effects for tuberculosis vaccine development.

May 17, 2026VaccinesOpen Access

Rv2656c: A Potential Candidate Antigen Associated with Latent Tuberculosis Infection

View Full Paper

Ask AI

Bookmark

Authors

YDYunjie Du PHPu He WDWenrui Dang

Discussion

Member takes

Overview

Randomized trial demonstrates immunogenicity and protective effects of Rv2656c in a mouse model, suggesting its potential for TB vaccine development.

Key Points

To identify and validate latency-associated antigens with immune-protective effects for tuberculosis vaccine development.
Combined bioinformatics with experimental validation to identify highly expressed antigens related to latent infections.
Evaluated immunogenicity in multiple mycobacterium infection models.
Performed immune response and protective effects assessment using various assays in a mouse model.
Rv2656c showed strong immunogenicity in humans and cattle, with significant inhibitory effects against Mycobacterium tuberculosis in MGIA.
Rv2656c enhanced macrophage-mediated phagocytosis and killing of Mycobacteria in vitro.
In LTBI mouse models, Rv2656c treatment significantly reduced bacterial load in the lungs.

Cite This Study

Du et al. (2026) studied this question.

synapsesocial.com/papers/6a095bdd7880e6d24efe1b10 https://doi.org/10.3390/vaccines14050442

View Full Paper

Ask AI

Bookmark

May 17, 2026VaccinesOpen Access

Rv2656c: A Potential Candidate Antigen Associated with Latent Tuberculosis Infection

View Full Paper

Ask AI

Bookmark

Authors

YDYunjie Du PHPu He WDWenrui Dang

Discussion

Member takes

Overview

Randomized trial demonstrates immunogenicity and protective effects of Rv2656c in a mouse model, suggesting its potential for TB vaccine development.

Key Points

To identify and validate latency-associated antigens with immune-protective effects for tuberculosis vaccine development.
Combined bioinformatics with experimental validation to identify highly expressed antigens related to latent infections.
Evaluated immunogenicity in multiple mycobacterium infection models.
Performed immune response and protective effects assessment using various assays in a mouse model.
Rv2656c showed strong immunogenicity in humans and cattle, with significant inhibitory effects against Mycobacterium tuberculosis in MGIA.
Rv2656c enhanced macrophage-mediated phagocytosis and killing of Mycobacteria in vitro.
In LTBI mouse models, Rv2656c treatment significantly reduced bacterial load in the lungs.

Cite This Study

Du et al. (2026) studied this question.

synapsesocial.com/papers/6a095bdd7880e6d24efe1b10 https://doi.org/10.3390/vaccines14050442

View Full Paper

Ask AI

Bookmark